Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

NCT00424229 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: LENALIDOMIDE

Sponsor

Groupe Francophone des Myelodysplasies